ESC 365 - SGLT2 inhibitor empagliflozin prevents anthracycline-induced cardiotoxicity in a large-animal model

ESC Professional Premium Access

SGLT2 inhibitor empagliflozin prevents anthracycline-induced cardiotoxicity in a large-animal model

Session: Novel targets against myocardial damage

Topic: Heart Failure

Speaker: Ms D. Medina-Hernandez (Madrid, ES)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Ms Danielle Medina-Hernandez

Spanish National Centre for Cardiovascular Research, Madrid (Spain)

0 follower

5 more presentations in this session

Renal Semaphorin 3C mediates cardiac adaptive response

Speaker: Mr Y. Otaki (Yamagata, JP)

Vaccination targeting senescence-associated transmembrane protein alleviated cardiovascular pathology in the mice

Speaker: Doctor C. Hsiao (Tokyo, JP)

Nap1L1 Ubiquitination Degradation-dependent Protective Effects of Wnt2 on Cardiac Ischemia/Reperfusion Injury

Speaker: Doctor Y. Wang (Shanghai, CN)

The development of small-molecule ERBB4 agonists as a treatment for heart failure

Speaker: Miss J. Cools (Antwerp, BE)

The protective role of Baz2b ablation in aging-related heart failure

Speaker: Mrs T. Zang (Shanghai, CN)

Access the full session

Novel targets against myocardial damage

Speakers: Ms D. Medina-Hernandez, Mr Y. Otaki, Doctor C. Hsiao, Doctor Y. Wang, Miss J. Cools...

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources